FOSB and skin basal cell carcinoma: Similar to our findings in the mouse BCC cell line, SMO plus AP-1 inhibitors have an additive effect in reducing Gli1 expression, while AP-1 plus ALK5 inhibitors do not (Supplementary Fig. 5i).